It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as CRISPR, followed by manual triage of significantly enriched genes. This triage process to identify ‘high value’ hits resulting from the CRISPR screen involves manual curation that requires specialized knowledge and can take even experts several months to comprehensively complete. To find key drivers of resistance faster we build a recommendation system on top of a heterogeneous biomedical knowledge graph integrating pre-clinical, clinical, and literature evidence. The recommender system ranks genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance. This unbiased approach identifies 57 resistance markers from >3,000 genes, reducing hit identification time from months to minutes. In addition to reproducing known resistance markers, our method identifies previously unexplored resistance mechanisms that we prospectively validate.
Resistance to EGFR inhibitors presents a major obstacle in treating non-small cell lung cancer. Here, the authors develop a recommender system ranking genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 AI Engineering, R&D IT, AstraZeneca, Biological Insight Knowledge Graph (BIKG), Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
2 Oncology R&D, AstraZeneca, Early Computational Oncology, Research and Early Development, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
3 Oncology R&D, AstraZeneca, Bioscience, Research and Early Development, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
4 IGNITE, AstraZeneca, NLP Lab, Enterprise AI Services, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
5 AI Engineering, R&D IT, AstraZeneca, Biological Insight Knowledge Graph (BIKG), Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403)
6 Discovery Sciences, R&D, AstraZeneca, Data Sciences & Quantitative Biology, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
7 Oncology R&D, AstraZeneca, Early Computational Oncology, Research and Early Development, Waltham, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493)